Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma

[1]  D. Milan,et al.  Dexamethasone suppresses long QT phenotype in patient with acute promyelocytic leukemia treated with arsenic , 2015, HeartRhythm case reports.

[2]  Jessica Katz,et al.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. , 2015, The New England journal of medicine.

[3]  R. Shah,et al.  ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies. , 2015, British journal of clinical pharmacology.

[4]  Don M. Benson,et al.  Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC , 2013, Cancer Immunology, Immunotherapy.

[5]  Mahmoud S. Assaf,et al.  Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men , 2013, Basic & clinical pharmacology & toxicology.

[6]  P. Sager,et al.  Electrocardiographic assessment for therapeutic proteins--scientific discussion. , 2010, American heart journal.

[7]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[8]  S. Rohatagi,et al.  Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs , 2009, Journal of clinical pharmacology.

[9]  Liudmila Polonchuk,et al.  Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. , 2008, Journal of pharmacological and toxicological methods.

[10]  N. Munshi,et al.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.

[11]  J. Mitcheson.  hERG potassium channels and the structural basis of drug-induced arrhythmias. , 2008, Chemical research in toxicology.

[12]  F. Zhan,et al.  CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.

[13]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[14]  Borje Darpo,et al.  ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs , 2005 .

[15]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[16]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[17]  M. Sadove,et al.  Sudden appearance of cardiac arrhythmias after dexamethasone. , 1972, JAMA.

[18]  P. Mathew,et al.  Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily , 2000, Immunogenetics.